Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Up 103.0% in December

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 121,000 shares, an increase of 103.0% from the December 15th total of 59,600 shares. Approximately 0.5% of the company’s stock are short sold. Based on an average daily trading volume, of 153,600 shares, the days-to-cover ratio is presently 0.8 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Bolt Biotherapeutics stock. FMR LLC raised its holdings in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 33.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 115,386 shares of the company’s stock after purchasing an additional 28,773 shares during the period. FMR LLC owned about 0.30% of Bolt Biotherapeutics worth $75,000 at the end of the most recent quarter. 86.70% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “neutral” rating on shares of Bolt Biotherapeutics in a report on Wednesday, November 13th. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $3.50.

Bolt Biotherapeutics Stock Up 0.2 %

NASDAQ:BOLT traded up $0.00 during midday trading on Thursday, reaching $0.52. 80,158 shares of the stock traded hands, compared to its average volume of 172,036. The business has a 50-day moving average of $0.57 and a two-hundred day moving average of $0.64. The stock has a market capitalization of $19.94 million, a PE ratio of -0.30 and a beta of 0.96. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.16 and a current ratio of 3.16. Bolt Biotherapeutics has a 12-month low of $0.48 and a 12-month high of $1.56.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04). The business had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $1.02 million. Bolt Biotherapeutics had a negative return on equity of 69.46% and a negative net margin of 665.56%. On average, equities analysts forecast that Bolt Biotherapeutics will post -1.61 earnings per share for the current fiscal year.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.